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Abstract 
 
Toxoplasma gondii is an obligate intracellular pathogen, and belongs to 
the phylum Apicomplexa. The pathogenesis of the parasite is thought to be due to, in 
part, repeated cycles of invasion of host cells, replication and lysis of host cells. T.gondii 
is a haploid organism and forward genetic methods to study invasion are hard to employ, 
because if genes essential to invasion are disrupted, they will be lethal to the parasite. 
Although conditional mutants have been generated, it is hard to generate a large library of 
conditional mutants. As an alternate approach, a library of small molecules can be 
screened in an assay for a particular phenotype. Then the target of the small molecule 
responsible for the phenotype can be identified. Two different small molecules screens 
can be performed: a non-presumptive approach using small molecules with no known 
targets or a hypothesis based approach using small molecules with known or 
hypothesized targets. Approximately 12,000 structurally diverse small molecules with no 
known target were tested in a high throughput screen in our lab to identify inhibitors of 
T.gondii invasion. 
 In this thesis I have described two different projects using small molecule 
inhibitors identified from this screen. My first project was hypothesis driven. One of the 
inhibitors identified, 118793, is structurally similar to a known inhibitor of mammalian 
cGMP Phosphodiesterase. The goal of the project was to test the hypothesis that cGMP 
Phosphodiesterase is the target of the compound 118793 during invasion. This hypothesis 
is also supported by the fact, that cGMP dependent protein kinase is important for 
invasion and motility of T.gondii. An in-vitro phosphodiesterase assay using tritiated 
cGMP as substrate and anion exchange chromatography was adopted to test the 
hypothesis. The effect of compound 118793 on the cGMP hydrolytic activity of 
phosphodiesterase in T.gondii extracts and purified bovine phosphodiesterase was tested. 
From our assay, compound 118793 does not appear to inhibit cGMP phosphodiesterase 
in T.gondii or purified cGMP Phosphodiesterase. In addition, I also generated a FRET 
based cGMP indicator called CYGNET 2.1 to test the hypothesis in vivo. 
The second project was to test the effect of the invasion inhibitors 
identified in our screen on T.gondii egress. The dogma in the field is that the process of 
invasion and egress are mechanistically similar. I thought it would of interest to 
determine if any of the small molecules inhibited invasion but not egress. I adopted an 
ionophore induced egress assay to address this question. Ionophore-induced egress is 
thought to involve active motility. I tested invasion inhibitors that inhibit motility and 
some that do not inhibit motility. From my assay, it appears that one of the motility 
inhibitors does not inhibit egress. In addition, two of the non-motility inhibitors inhibit 
egress. These results prompt us to revisit current theories about invasion and egress. 
Given the limitations we have to study T.gondii, small molecule approach 
has proven to be very useful and advantageous in identifying proteins and pathways 
involved in invasion. 
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 CHAPTER I 
 
Introduction 
Toxoplasma gondii is an obligate intracellular parasite that can infect 
almost all warm-blooded vertebrates including man. T. gondii is the causative agent of 
toxoplasmosis. In most cases, toxoplasmosis is asymptomatic because of effective 
protective immunity in healthy individuals. However, it may prove fatal in 
immunocompromised people. Toxoplasmosis, when transmitted congenitally from 
mother to the unborn fetus, may result in severe birth defects and death in some cases.   
T. gondii belongs to the phylum Apicomplexa and is an excellent model for studying 
other apicomplexans such as Plasmodium (causes malaria) and Cryptosporidium (causes 
cryptosporidosis) (Roos, Crawford et al. 1999; Kim and Weiss 2004).  
The life cycle of T. gondii includes both a sexual and an asexual phase. 
The sexual phase takes place in the definitive hosts, which are all members of the family 
Felidae (e.g., domestic cats). During the sexual phase, oocysts develop in the intestine of 
the cat. The oocysts are shed in the cat faeces, and contain the highly invasive 
sporozoites. Animals and humans are the intermediary hosts and are infected by ingesting 
food and water contaminated by oocysts shed in cat feces. The asexual phase of the life 
cycle takes place in any warm-blooded intermediate host ingesting the oocyst. Once 
inside the intermediate host, the tachyzoites, which are the fast growing forms, begin the 
asexual life cycle. They cause acute infections, however the host immune response clears 
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the infection effectively. Cytokines such as IL-12 and IFN-γ are produced by the 
dendritic, natural killer and T cells of the host (Yap and Sher 1999). In 
immunocompromised people such as people with AIDS, the parasites continue 
replicating as tachyzoites within a vacuole known as the parasitophorous vacuole (PV), 
surrounded by the parasitophorous vacuole membrane (PVM).  
 However, in immunocompetent hosts, the host immune response to the 
primary infection forces the tachyzoites to switch into bradyzoites. The bradyzoites are 
the slow growing forms and replicate within the host cells to form tissue cysts. 
Intermediate hosts can also be infected by ingesting these tissue cysts in unwashed 
vegetables, or improperly cooked meat. The life cycle of T. gondii completes a full circle 
when cats ingest these tissue cysts. Tissue cysts can grow in any organ, but are 
predominant in the brain and muscles. As they are the resistant to the host immune 
response, bradyzoites cause a chronic infection. In immunocompromised patients with a 
weak immune system the bradyzoites switch back into tachyzoites and the cycle 
continues. Small populations of bradyzoites spontaneously switch back to tachyzoites in 
immunocompetent individuals as well. 
The apical end of the T. gondii consists of the conoid, two intraconoid 
microtubules, and two polar rings. The conoid is made of a unique polymer form of 
tubulin (Hu, Roos et al. 2002). It looks like a compressed spring and it repeatedly 
protrudes and retracts during motility. Conoid protrusion can be induced using calcium 
ionophores (Mondragon and Frixione 1996; Monteiro, de Melo et al. 2001). The actual 
function of the conoid is yet unknown.  
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In the apical end of the parasite, there are two types of secretory organelles 
known as the micronemes and the rhoptries. The micronemes are tubular structures and 
the microneme proteins contain conserved domains, especially thrombospondin-like 
motifs, which suggest that they may play an important role in adhesion (Wan, Carruthers 
et al. 1997). TgMIC 1-4 have been shown to bind to host cells (Fourmaux, Achbarou et 
al. 1996). Microneme proteins are secreted by extracellular parasites constitutively (Wan, 
Carruthers et al. 1997)  and secretion can be upregulated using calcium ionophores 
(Carruthers and Sibley 1999). The above observation and other studies (Carruthers, 
Moreno et al. 1999; Carruthers and Sibley 1999; Lovett, Marchesini et al. 2002; Lovett 
and Sibley 2003) have shown that intracellular calcium levels of parasites affect the 
secretion of microneme proteins. During invasion, it has been shown that secretion of 
microneme proteins increases (Carruthers and Sibley 1997) and that they have to undergo 
proteolytic processing for proper targeting and function (Brossier, Jewett et al. 2005; Teo, 
Zhou et al. 2007). TgMIC2 is a very well studied microneme protein. It is a 
transmembrane protein and is secreted to the surface of the parasite during invasion. It is 
translocated to the posterior of the parasite as it enters the host cell. At or near the 
posterior end of the parasite TgMIC2 is cleaved within its transmembrane domain by 
rhomboid proteases (Dowse and Soldati 2004; Dowse, Pascall et al. 2005). This 
intramembrane cleavage results in the shedding of the extracellular domain of TgMIC2.  
TgMIC 3,5 and 6 are proteolytically cleaved intracellularly during transport to the 
micronemes (Brydges, Sherman et al. 2000; Opitz, Di Cristina et al. 2002; Brydges, Zhou 
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et al. 2006). TgMIC4 and TgMIC8 are also shed during invasion (Brecht, Carruthers et 
al. 2001; Meissner, Reiss et al. 2002).  
The rhoptry organelles are club shaped and secrete their contents during 
invasion as well. Rhoptry proteins play a critical role in formation of the tight junction 
(Alexander, Mital et al. 2005; Lebrun, Michelin et al. 2005), during invasion (Dubremetz 
2007), and in host-parasite interaction (Saeij, Boyle et al. 2006; Taylor, Barragan et al. 
2006), some rhoptry proteins are incorporated into the PVM after invasion (Beckers, 
Dubremetz et al. 1994). The rhoptry proteins also undergo proteolytic cleavage for proper 
function and targeting (Soldati, Lassen et al. 1998). The rhoptry proteins include many 
different kinases, proteases and phosphatases that may play a crucial role during invasion 
(Saeij, Boyle et al. 2006; Taylor, Barragan et al. 2006; Gilbert, Ravindran et al. 2007). 
Recently, it was shown that ROP 16 and ROP 18 are important for virulence of the 
parasite (Saeij, Boyle et al. 2006; Taylor, Barragan et al. 2006). 
Another type of secretory organelle called the dense granules are present 
in the parasite. They are spread throughout the parasite and are exocytosed by the 
tachyzoites when they are inside the PV (Leriche and Dubremetz 1990). Some of the 
dense granule proteins are secreted constitutively and thought to play a role in host 
immune response (Vercammen, Scorza et al. 2000)  and in modifying the parasitophorous 
vacuole (Leriche and Dubremetz 1990; Achbarou, Mercereau-Puijalon et al. 1991; 
Lecordier, Mercier et al. 1993; Lecordier, Moleon-Borodowsky et al. 1995; Cesbron-
Delauw, Lecordier et al. 1996; Vercammen, Scorza et al. 2000) . 
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The periphery of the parasite consists of a plasma membrane and the two 
membranes of the inner membrane complex (IMC), a continuous layer of flattened 
vesicles underlying the plasma membrane (Mann and Beckers 2001). Below the IMC, 
there are 22 subpellicular microtubules, which run three fourths the length of the parasite. 
However, the IMC is found along the whole length of the parasite (Morrissette, Murray et 
al. 1997). 
The pathology of T. gondii infections is thought to be due to the host 
immune response and lesions caused by host cell lysis. T. gondii invades almost any 
nucleated cell, replicates within the host cells and lyses out causing lesions. The process 
of T. gondii invasion is quite complex and parasite driven. There are two main steps 
during invasion, attachment and penetration. The parasite glides over the host cell surface 
by a process known as gliding motility. This type of motility does not involve any cell 
extensions or morphological changes. It is powered by an actin-myosin based motor 
complex known as the glideosome. The glideosome is a complex of myosin and three 
other proteins known as GAP45, GAP50 and the myosin light chain. (Opitz and Soldati 
2002). The glideosome is anchored in the IMC by GAP50, which is an integral 
membrane glycoprotein (Gaskins, Gilk et al. 2004). Most proteins involved in gliding 
motility and in the invasion machinery are highly conserved within the apicomplexans ( 
Opitz and Soldati 2002; Keeley and Soldati 2004; Baum, Richard et al. 2006). Upon 
some unknown recognition event, the parasite attaches to the host cell. The secretory 
organelles secrete their contents sequentially namely, micronemes, rhoptries and then 
dense granules (Carruthers and Sibley 1997). Microneme proteins MIC2-4 form the 
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bridge between the glideosome and the substrate. As the parasite invades the host cell, a 
moving junction forms at the point of entry. The moving junction is evident as a 
constriction of the host plasma membrane around the parasite (Aikawa, Komata et al. 
1977; Alexander, Mital et al. 2005). As the parasite invades, the moving junction moves 
from the anterior to the posterior of the parasite. The apical membrane antigen 1 
(AMA1), secreted from the micronemes, is associated with at least two other rhoptry 
proteins at the moving junction (Alexander, Mital et al. 2005; Lebrun, Michelin et al. 
2005) . During invasion the parasite becomes surrounded by the PVM, made primarily of 
host cell plasma membrane (Suss-Toby, Zimmerberg et al. 1996).  
After invasion is complete, the parasite resides and replicates within the 
PV. When the vacuole is filled with approximately 128 parasites, the parasites lyse open 
the host cell and egress to reinvade neighboring host cells. Parasites treated with 
cytochalasin D were unable to egress, suggesting active motility is required during the 
process (Black, Arrizabalaga et al. 2000; Moudy, Manning et al. 2001). It was earlier 
thought that parasites just rupture the host cells during egress. However, it has been 
shown that a moving junction is formed, similar to the one during invasion, and the 
parasites actively egress out of the host cell (Black and Boothroyd 2000; Hoff and 
Carruthers 2002; Arrizabalaga and Boothroyd 2004). Increases in intracellular calcium 
induce egress (Black, Arrizabalaga et al. 2000).  
As mentioned earlier, T. gondii is a good model to study invasion by 
apicomplexans. In our lab, we are interested in the process of invasion of T. gondii into 
host cells. Using a novel small molecule approach we are trying to identify important 
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proteins and pathways involved in invasion. One of these proteins or pathways could 
eventually prove to be a good drug target for treatment of toxoplasmosis. 
Background of small molecule screen 
 
Invasion is one of the important aspects of the pathogenesis of T. gondii 
infection. A better understanding of the molecular mechanisms of invasion will be useful 
in developing drugs and vaccines for toxoplasmosis. T. gondii is a haploid organism, thus 
using forward genetic methods to study invasion is problematic. Disrupting an essential 
gene for invasion could prove lethal to the parasite and thus recovering mutants of 
interest will be challenging. Generating conditional mutants have alleviated this problem 
(Pfefferkorn and Pfefferkorn 1976; Meissner, Brecht et al. 2001; Mital, Meissner et al. 
2005; White, Jerome et al. 2005; Mazumdar, E et al. 2006). However, it is not feasible to 
generate a large number of conditional mutants. An alternate approach to study invasion 
is to screen a library of structurally diverse small molecules for their effect on invasion. 
The small molecule approach has been a very useful tool for studying a variety of cell 
biological phenomena. For example, small molecules have been useful in identifying and 
characterizing proteins and functions of the eukaryotic cytoskeleton (Peterson and 
Mitchison 2002).  
Our lab screened 12,160 structurally diverse small molecules using a high 
throughput invasion assay (Carey, Westwood et al. 2004). 24 inhibitors of invasion were 
identified from this screen. Unexpectedly, six enhancers of invasion were identified as 
well. Chapter 2 of this thesis was undertaken to test the hypothesis that one of the 
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inhibitors  identified in this screen, 118793, is an inhibitor of cGMP phosphodiesterase 
(cGMP PDE). In the work described in Chapter 3, I tested whether the inhibitors of 
invasion also inhibit egress.  
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CHAPTER II 
 
Target identification of 118793 
 
Introduction 
From the high throughput screen described in chapter 1, 24 inhibitors of  
T. gondii invasion were identified (Carey, Westwood et al. 2004). One of the inhibitors, 
118793 (Fig II-1), is structurally identical to monastroline (HR22C16), an inhibitor of the 
mammalian kinesin Eg5 (Hotha, Yarrow et al. 2003). 118793 is also structurally similar 
to Tadalafil (Cialis), an inhibitor of mammalian cyclic guanosine monophosphate 
phosphodiesterase (cGMP PDE) (Daugan and Labaudiniere 2000; Daugan, Grondin et al. 
2003; Daugan, Grondin et al. 2003).  
118793 is an irreversible inhibitor of invasion. 118793 inhibits invasion at 
concentrations as low as 12.5 μM. It inhibits motility, at concentrations as low as 25 μM. 
It inhibits both constitutive and induced microneme secretion. 118793 targets the parasite 
and not the host cell during invasion (Carey, Westwood et al. 2004). 
                  
Figure II- 1 Structure of 118793 
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Although 118793 is structurally identical to monastroline, from the 
bioinformatics work and structural analysis studies described below, kinesins seem an 
unlikely target.  
Bioinformatic analysis of Toxoplasma gondii kinesins 
Keyword search for the word “Kinesin” in ToxoDB identified 19 
protein/genes as kinesins. However, after performing a BLASTP search, only 15 of those 
proteins/genes contain a predicted kinesin motor domain. 
Of the 15 proteins, eight are expressed in tachyzoites, two in bradyzoites 
and two in oocysts. No ESTs were identified for four of the 15 protein/genes. Eg5 
belongs to the family 5 kinesins in mammals. Comparison of the conserved regions of 
different families of kinesins was performed using BLASTP. Four of the 15 
proteins/genes had similarity to family 5 kinesin, and at least three out of the four are 
expressed in tachyzoites. 
Through hydrogen/deuterium exchange mass spectrometry, two regions 
forming the inhibitor-binding pocket of Eg5 where identified (Brier, Lemaire et al. 2006). 
Comparing the sequence alignments of these two regions and the four family 5-like 
genes, only two out of the four genes had similarities in region I. All four genes had 
similarities in region II. However, since we do not know which of the residues are 
required for inhibitor binding, it is hard to tell if 118793 interacts with these four proteins 
in T. gondii. A collection of 480 inhibitors with known targets were tested in our invasion 
assay (unpublished data). None of the known kinesin inhibitors in this collection 
inhibited T. gondii invasion. Furthermore, Eg5 is involved in mitosis in mammals. Even 
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if the Eg5 like kinesins were involved in mitosis in T. gondii, no mitosis occurs within the 
20-30 second window of T. gondii invasion. These data suggest that kinesins may not be 
the target of the 118793 during invasion. 
cGMP and cGMP PDE 
The goal of my project was to test if cGMP PDE was a target of 118793 
during invasion. cGMP is a second messenger molecule produced by an enzyme called 
guanylate cyclase. Two types of guanylate cyclases are found in most cells: particulate 
guanylate cyclases and soluble guanylate cyclases. Peptide ligands and nitric oxide 
stimulate the production of cGMP by particulate gunaylate cyclase and soluble guanylate 
cyclase respectively (Zhao, Brandish et al. 1999; Davies 2006). Some of the known 
downstream targets of cGMP are cyclic nucleotide gated channels (CNGs), cGMP-
regulated phosphodiesterases (cGMP-PDEs) and cGMP-dependent protein kinases 
(PKGs) (Davies 2006).  
                           When cGMP binds to cyclic nucleotide-gated (CNG) channels it opens 
the channels, which brings about a change in concentrations of various ions, especially 
calcium (Davies 2006). Ca2+/calmodulin and phosphorylation regulate the activity of 
CNG channels. CNG channels are found in many different type of cells, but 
predominantly in neurons (Kaupp and Seifert 2002). However, the exact function of 
cyclic nucleotide-gated (CNG) channels is known only in in retinal photoreceptors (Yau 
and Baylor 1989) and in olfactory epithelium (Nakamura T 1987).  
The cGMP dependent protein kinases (PKG) are serine/threonine kinases 
found in many different eukaryotic organisms and cells (Francis and Corbin 1999; 
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Hofmann, Feil et al. 2006). PKG is a soluble enzyme, and enriched in cells like smooth 
muscle cells, neuroblastoma and glioma hybrid cells and Purkinje cells. A single gene 
encodes both the catalytic and regulatory domains (containing cGMP-binding sites) of 
PKG, in contrast to different genes encoding the two domains of PKA (cAMP-dependent 
protein kinase) (Francis and Corbin 1999).  
In the absence of cGMP, the N terminus of PKG interacts with the 
catalytic domain. Thus, the protein is inactive. When cGMP is present, it binds to the 
regulatory domain, which in turn causes a conformational change. This results in the 
release of the N terminus from the catalytic domain. Activated PKG can then 
phosphorylate its substrates such as myosin light chain phosphatase in smooth muscle 
cells. Phosphorylated myosin light chain phosphatase in turn dephosphorylates the 
myosin light chain resulting in muscle relaxation (Wikipedia)(Wu, Haystead et al. 1998).  
All PKG sequences known so far contain two cGMP-binding sites, 
however, apicomplexans PKGs have three cGMP-binding sites (Deng, Parbhu-Patel et al. 
2003). Apicomplexan parasite PKGs are specific drug targets. The inhibitor, known as 
compound 1 (a trisubstituted pyrrole, 4-[2-(fluorophenyl)-5-(1-methylpiperidine-4-yl)-
1H-pyrrol-3-yl]pyridine), was active against a number of apicomplexan parasites. It has 
been demonstrated conclusively that the parasite PKG is the primary target of compound 
1 (Donald, Allocco et al. 2002). PKG could only be disrupted in   T. gondii, which is a 
haploid organism, in the presence of an episomal copy of the gene. This suggested that 
PKG is an essential protein in apicomplexans. 
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 E. tenella and T. gondii mutant PKGs with greatly reduced binding 
affinity for compound 1 were generated by site directed mutagenesis. This provided 
further evidence that PKG is the primary target for compound 1. It has now been shown 
that compound 1 prevents attachment of E. tenella sporozoites and T. gondii tachyzoites 
to host cells, but also inhibits gliding motility and cell invasion (Wiersma, Galuska et al. 
2004). Inhibition of gliding motility and cell invasion by compound 1 did not occur in 
parasites expressing compound 1-insensitive PKG mutants, implying an important role 
for PKG in these events. 
   The intracellular concentration and duration of cGMP levels is regulated by 
the activity of phosphodiesterases (PDE). More than one type of PDE can be found in a 
single cell. cGMP levels are modulated by the activity of specific PDEs and the 
localization of the PDEs in the cell. On the other hand, the activity of PDE can be 
regulated by cGMP, phosphorylation, dephosphorylation, Ca2+/ calmodulin, and 
interactions with other proteins (Bender and Beavo 2006). There are 11 families of 
mammalian PDEs (Bender and Beavo 2006). All PDEs have a catalytic domain and a 
regulatory domain. All 11 families are highly conserved in the catalytic domain. Of the 
11 families PDE 1, 2, 5, 6 and to a lesser extent 10 and 11 are cyclic nucleotide PDEs. 
These enzymes have two cGMP binding sites, known as GAF A and GAF B domains, in 
their regulatory domain. Binding of cGMP regulates their activity because they are 
conformationally sensitive to cGMP (Bender and Beavo 2006). 
  PDE 1 is a calcium/ calmodulin dependent PDE that hydrolyses both cAMP 
and cGMP. The specificity for the two nucleotides is different for the different isoforms 
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of the PDE 1 family enzymes. PDE 2 family enzymes also hydrolyse cAMP and cGMP. 
Binding of cGMP to the GAF B domain regulates the activity of PDE 2 enzymes. PDE 3 
family members hydrolyse both cGMP and cAMP. However, the cAMP hydrolyzing 
activity is inhibited in the presence of cGMP. Thus PDE 3 family is also the cGMP 
inhibited PDE family. PDE 5 family members also have the GAF domains and are thus 
regulated by the binding of cGMP. However, in contrary to PDE 2 cGMP binds to the 
GAF A domain of PDE 5 enzymes. PDE 6 is known as the photoreceptor 
phosphodiesterase. It is predominantly expressed in the photoreceptor outer segment of 
the retina. PDE 10 also contain the GAF domain, however they bind cAMP and not 
cGMP. PDE 11 hydrolyzes both cAMP and cGMP. However, it contains the GAF 
domains which are regulated by cGMP binding (Bender and Beavo 2006).  
  There are many different isoforms of PDE and each has a distinct architecture 
at the active site. This makes them a very good therapeutic target for various diseases and 
conditions. For example, Sildenafil, Tadalafil and Vardenafil are clinically used 
inhibitors of PDE 5 to treat erectile dysfunction. All three drugs bind to the catalytic site 
of PDE 5. The residues and domains they bind to make them very specific PDE 5 
inhibitors. Rolipram is a specific inhibitor of PDE 4.  
        As mentioned earlier, 118793 is structurally similar to Tadalafil. From the 
bioinformatics work described below, there are 16 PDE domain-containing protein/genes 
in T. gondii. However, none have any homology to mammalian PDE 5. I continued to test 
if cGMP PDE is a target of 118793 because there was some preliminary data supporting 
this hypothesis (Kim Carey and Gary Ward, unpublished data). PDE Assays were 
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performed using a fluorescent substrate and purified bovine PDE. In these assay 118793 
appeared to inhibit purified PDE. In addition, this hypothesis is supported by studies 
implicating cGMP and cGMP dependent protein kinase (PKG) in invasion (Wiersma, 
Galuska et al. 2004; Donald, Zhong et al. 2006). Using an inhibitor of PKG, Compound 
1, it was shown that PKG is required for motility and invasion (Gurnett, Liberator et al. 
2002).  
Bioinformatic analysis of cGMP PDEs 
A keyword search for the word “Phosphodiesterase” in ToxoDB identified 
21 protein/genes as putative PDEs. Of these, only 16 (gene identification numbers listed 
below) contain the PDE conserved catalytic domain. 
20.m03727 44.m02764 57.m03117 72.m00380  
641.m01498 83.m01190       39.m00361 44.m02765  
583.m05366 42.m03630 42.m03528      42.m03383  
49.m03267 59.m03644 55.m04764 55.m00270 
When I looked for ESTs in ToxoDB, 5 are expressed in tachyzoites, 4 are 
expressed in both tachyzoites and bradyzoites, 1 in oocysts and 6 are non-stage specific.  
Tachyzoite ESTs Bradyzoite ESTs Oocyst ESTs      Unclear (no ESTs) 
20.m03727  49.m03267  55.m04764  39.m00361  
42.m03383  57.m03117     42.m03630  
42.m03528  83.m01190      44.m02764 
49.m03267  72.m00380     44.m02765 
55.m00270        59.m03644 
 19
Tachyzoite ESTs Bradyzoite ESTs Oocyst ESTs      Unclear (no ESTs) 
57.m03117        641.m01498 
583.m05366 
83.m01190 
72.m00380 
   
Experimental approach 
I approached the question if 118793 inhibits cGMP PDE during invasion 
both in vivo and in vitro. I performed in vitro PDE assays, in the presence and absence of 
118793 using fluorescent and radiolabeled substrates. I eventually abandoned the 
fluorescent substrate-based assay, as the assay gave variable results. The variability was 
compounded by the fact that 118793 is also fluorescent at the same wavelengths as the 
substrate. I have described the approach using radiolabeled substrate below. I also 
generated a fluorescent cGMP indicator to test the hypothesis in vivo as described below. 
II.A In vitro PDE assay using radiolabeled substrate 
Principle 
3[H] cGMP is hydrolyzed to the radiolabeled 5’ nucleotide product 3[H] 
GMP, by PDE (parasite extract). GMP is then hydrolyzed to the corresponding 
nucleoside, 3[H] guanosine, using snake venom (nucleotidase) (Figure II-2). cGMP and 
GMP are negatively charged and bind to an anion exchange column. Guanosine is 
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uncharged and will flow through when eluted with water. I measured the radioactivity in 
the flow-through, which is a measure of the PDE activity in the parasite extract.        
    
Figure II- 2 Conversion of 3H- cGMP to 3H- guanosine in the cGMP PDE assay 
 
Method 
The assay was performed as previously described (Thompson, Brooker et 
al. 1974). The enzyme diluent ( 50 mM Hepes at pH 7.2, 0.5 mg/ml ovalbumin and 0.1 
mg/ml protease inhibitor (Sigma) ) and reaction mix (500 μM tritiated cGMP, 0.5 μM 
cold cGMP, 1 mM magnesium chloride, 0.2 mg/ml ovalbumin, 0.1 mM EDTA and 50 
mM Hepes, pH 7.4) were prepared as described (Thompson, Brooker et al. 1974). 
Purified bovine heart PDE (dissolved in 50 % glycerol to final concentration of 0.005 
units /μl) and snake venom were purchased from Sigma. Parasites were harvested and 
extracted in Tris-buffer (0.1 M Tris-HCl, 20 mM magnesium chloride and 10 mM 
calcium chloride) with 0.5 % Triton X-100 and protease inhibitors. To prepare the anion 
exchange column; 100 ml of the Sephadex resin was precycled with water (2X), 0.1 N 
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hydrochloric acid (1X), water (2X), 0.1 N sodium hydroxide (1X) , water (2X), 0.1 N 
hydrochloric acid (1X) and water (4X). pH was adjusted to 7 with 50 mM Hepes at pH 8. 
Disposable polypropylene columns (Biorad) were packed with 4ml resin before use. 
For the PDE assay, the enzyme diluent (60 μl), an appropriate amount of 
enzyme or parasite extract (final volume 40 μl) and reaction mix (200 μl) were mixed on 
ice. The total reaction was incubated at 30˚C for 30min. The reaction was stopped by 
adding 100 μl 0.25 M hydrochloric acid and neutralized with 0.25 M sodium hydroxide. 
To the reaction, 100 μl of snake venom was added and incubated at 30˚C for 30 min. The 
total reaction was added to the columns and eluted with 8 mls of water. 1 ml of the eluate 
was mixed with 10 ml of scintillation fluid and counted. 118793 (from a 40 mM stock) or 
equivalent volumes of DMSO were added to the reaction just before adding the reaction 
mix.  
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 Results 
(i) I have tested and seen activity with 2 x 10 7 to 2 x 10 8 tachyzoites. The following 
graph represents an assay with increasing amounts of parasite extract, done in duplicate 
(Figure II-3). As can be seen, the activity measured is roughly proportional to the amount 
of extract added. 
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Figure II- 3 PDE assay with parasite extracts 
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  (ii) I then tested whether 118793 inhibits PDE activity in the parasite extracts (Figure II-
4). I pretreated 5 x 10 7 parasites with 100 μM 118793, IBMX (positive control) or 
DMSO for 15min, extracted the parasites and did a 30min assay. The PDE control is 
untreated parasite extract. From this assay it did not seem like parasite PDE was inhibited 
by 118793. In fact, even the positive control IBMX does not seem to inhibit. 
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Figure II- 4 PDE assay with parasites extracts- compound added before extraction 
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  (iii) I repeated the assay by adding the compounds directly to the extracts without pre-
treatment (Figure II-5) . The compounds still do not seem to inhibit. 
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Figure II- 5 PDE assay with parasite extracts- compound added after extraction 
 
 
(iv) I next tested different concentrations of IBMX (25μM to 300μM) (data not shown). I 
still saw no inhibition with IBMX. It is possible that IBMX does not inhibit PDE in        
T. gondii. The other possibility is that the activity we see is not actually due to PDE in the 
extract but some other activity that hydrolyzes cGMP.  
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(v) I repeated all assays with commercial bovine brain PDE (crude preparation; undefined 
isoforms) to make sure that the IBMX is active (Figure II-6). I first made sure that I could 
see activity with the store bought PDE in my assay. The following graph represents the 
direct correlation between increasing amounts of PDE and the measured activity of PDE. 
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Figure II- 6 PDE assay with purified bovine PDE 
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vi) I then tested the effect of 118793 and IBMX on the bovine PDE, at 300 μM and 100 
μM (Figure II-7). As seen from the graph below, IBMX inhibited approximately 50 % of 
PDE activity. However, 118793 did not inhibit activity even at 300μM. 
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Figure II- 7 PDE assay with purified PDE in the presence of compounds 
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vii) When a dose response assay was done, I saw the same pattern (Figure II-8). IBMX 
inhibited bovine PDE activity in a dose dependent manner, while 118793 did not inhibit 
activity. The following graph shows the results of the assay done in duplicate. 
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Figure II- 8 PDE assay with purified PDE in the presence of compounds at different 
concentrations 
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 viii) From the above results it was clear that 118793 did not inhibit bovine PDE. IBMX 
inhibited up to 50% of bovine PDE activity, however it did not affect the activity in 
parasite extracts. It is possible that the level of PDE is very low in RH strain, so I decided 
to repeat the assay with PTG strain parasites (because RH and P strain parasites show 
differences in cyclic nucleotide metabolism (Kirkman, Weiss et al. 2001). As seen from 
the following graph (Figure II-9), there was no difference between RH and PTG 
parasites. 
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Figure II- 9 PDE assay w
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ix) I then tested RH, PTG and purified PDE at the same time (Figure II-10). IBMX still 
inhibited purified PDE, but had no detectable effect on RH or PTG extracts. 
                   
 
Figure II- 10 PDE assay with parasite extracts and purified PDE 
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Discussion 
 
From the assays it is clear that there is no inhibition of PDE activity by IBMX in parasite 
extracts. There are four possible explanations for the results: A) The activity I see with 
parasite extracts may in fact not be due to PDE. It could be that the membrane and other 
cellular debris in the extracts caused the counts to flow through the ion exchange column;  
B) The level of PDE could be too low in the extracts to see any differences that exist; C) 
Parasite PDE is not inhibited by IBMX; D) Parasite PDE may be inactive or denatured 
during the preparation of the parasite extracts. Due to the lack of a positive control, it is 
hard to conclude if 118793 inhibits PDE in parasite extracts. However, IBMX inhibits 
50% of purified PDE activity but 118793 does not inhibit purified PDE.  
Future experiments could include spinning down the parasite extracts and 
repeating the experiments with the supernatant. This will clear the membranes and other 
debris, which may be causing counts to flow through the column non-specifically. To 
address the question if parasite PDE is inactivated during the extraction procedure, 
parasite extracts could be prepared by alternative methods. The extraction could be done 
using different detergents, homogenization or in different buffers. An alternative 
approach to the anion exchange method could be to detect the products of the assay using 
thin layer chromatography (Bohme and Schultz 1974).  
Although 118793 has no effect on purified PDE, it is still worth pursuing 
the question as to whether parasite cGMP PDE is inhibited by 118793. The inhibitor of 
mammalian cGMP PDE, which is structurally similar to 118793, is a highly specific 
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inhibitor of PDE 5. However, it also inhibits other PDE isoenzymes to much lesser 
extent. PDE 6 is inhibited 10 fold less than PDE 5 and there are PDE 6-like PDEs in        
T. gondii. Another reason to pursue the question is there are four possible stereoisomers 
of 118793. Three are active and inhibit invasion while one is inactive. If 118793 inhibits 
parasite PDE, it will be interesting to see the correlation or lack thereof between the 
effects of the stereoisomers on invasion and PDE activity. 
II.B Fluorescence resonance energy transfer (FRET) and 
CYGNET 2.1 (cyclic GMP indicators using energy transfer) 
 
To address whether 118793 inhibits cGMP PDE in vivo, I tried to express 
a FRET indicator of cGMP in intact cells. CYGNET 2.1 (Honda, Sawyer et al. 2005) is a 
genetically encoded indicator of cGMP. Such indicators are very sensitive and are a 
useful tool to study signaling in different organisms. They are especially helpful in 
studying dynamic changes in levels of the signaling molecules. CYGNET 2.1 is used to 
measure the levels of cGMP in live cells. However, modified versions of these FRET 
based indicators have also been used successfully to study calcium (Honda, Moosmeier et 
al. 2005; Honda, Sawyer et al. 2005) and cAMP (Miyawaki, Llopis et al. 1997; 
Miyawaki, Griesbeck et al. 1999). CYGNET 2.1 is highly selective for cGMP, because 
the indicator contains PKG, which is conformationally sensitive to levels of cGMP. The 
binding of cGMP to PKG is reversible, making studies of dynamic interactions and 
changes of cGMP possible using CYGNET 2.1. CYGNET 2.1 has been useful in 
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studying changes in cGMP levels in single cells without affecting any other cell 
processes (Honda, Adams et al. 2001; Sawyer, Honda et al. 2003).  
Principle 
CYGNET 2.1 consists of a portion of the PKG protein flanked by CFP and 
Citrine. Residues 1-77 from the N-terminus of the PKG protein are deleted and Thr516 is 
mutated to alanine rendering it catalytically inactive (Figure II-11). There are many 
advantages of using PKG in the CYGNET 2.1 indicator. PKG is not restricted to 
membranes, it has a very high affinity for cGMP and it undergoes a conformational 
change in response to binding cGMP (Ruth, Landgraf et al. 1991; Zhao, Trewhella et al. 
1997; Wall, Francis et al. 2003). The principle behind the CYGNET 2.1 indicator system 
is that when PKG is not bound to cGMP, the fluorophores CFP and Citrine are close 
enough to each other that FRET transfer can occur from CFP to Citrine. When CFP is 
excited at 440nm, it emits at 475nm. Citrine, when excited at 475nm, emits at 525nm. 
Using a dual emission florescence microscope, emission can be measured at both 
wavelengths and the FRET ratio of CFP/Citrine can be calculated. When cGMP is bound 
to PKG, PKG undergoes a conformational change, which moves CFP and Citrine further 
from each other. This decreases the energy transfer from CFP to Citrine and there is a 
decrease in CFP/Citrine FRET ratio (Figure II-12). 
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Figure II- 11 CYGNET 2.1 
 
YGNET 2.1 
 
   
CYGNET 2.1 is made of  PKG flanked by two YFP mutants, CFP and Citrine. Changing 
Threonine 516 to Alanine as shown in the figure catalytically inactivates PKG. The two cGMP 
binding domains of PKG are labeled cGMP in the figure (adapted from Honda, 2001) 
 
 
 
 
Figure II- 12 FRET with CYGNET 2.1 
                      
 
 
 
 
 
When cGMP is not bound to PKG, CFP and Citrine are in close proximity. Thus, when 
excited at 440nm, CFP emits at 475nm; this fluorescence energy is transferred to Citrine, 
which in turn emits at 525nm. When cGMP is bound to PKG, fluorescence energy transfer 
between CFP and Citrine decreases. Thus emission from Citrine decreases. Using a dual 
emission microscope, emissions at both 475nm and 525nm are measured to calculate the 
CFP/Citrine FRET ratio (adapted from Honda, 2005). 
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 Method 
Cloning of CYGNET 2.1 
The CYGNET 2.1 construct was acquired from Dr. W Dostmann, UVM. 
Because the CFP and Citrine sequences are the same except for one amino acid change in 
the middle, PCR amplification of the whole CYGNET 2.1 construct was very 
challenging. CYGNET 2.1 was therefore cloned into the T. gondii expression vector in 4 
steps (Figure II-13). CFP and PKG with Bgl II and Nhe I restriction sites on the 3’ and 5’ 
end respectively were generated by PCR. Digesting with Nhe 1 results in a compatible 
cohesive end with AvrII. A T. gondii expression vector was digested with Bgl II and Avr 
II. The CFP and PKG fragment was ligated to the expression vector. YFP already present 
in the vector was then converted to Citrine using site directed mutagenesis. 
 
Figure II- 13 CYGNET 2.1 Cloning strategy 
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 Figure II- 14 CYGNET 2.1 cloned into T.gondii expression vector 
                                
Transfection of T. gondii 
Approximately 400 μg of the T. gondii expression vector CYGNET 2.1 
(Figure II-14) was purified by phenol/ chloroform extraction and ethanol precipitation 
and  resuspended in cytomix (120 mM potassium chloride, 0.15 mM calcium chloride, 10 
mM potassium phosphate at pH 7.6, 25 mM Hepes-potassium hydroxide at pH 7.6, 2 mM 
EDTA and 5 mM magnesium chloride).  Parasites were harvested and resuspended at 2 x 
107 /ml in cytomix. 6.6 x 107parasites were mixed with the DNA and transfected by 
 36
electroporation. Approximately 24 hrs later, parasites were harvested and suspended at 1 
x 107parasites/ml in 1% PBS. Parasites that emitted at 525 nm when excited at 488 nm 
were collected in the cell sorter. To make sure that the parasites are viable the drop drive 
frequency was set at 23.9 KHz and parasites collected at a rate of 800 particles/sec. Using 
the automatic cell deposition unit the parasites were sorted into a 96 well plate, with 
either 1 or 5 parasites per well. The parasites that grew up were then passaged under 
chloramphenicol selection. 
Immunofluorescence Assay 
Human foreskin fibroblasts were incubated with the CYGNET 2.1 
transfected parasites overnight. Coverslips were washed and fixed in paraformaldehyde 
and gluteraldehyde. The primary antibodies used were rabbit anti PKG antibody 
(Stressgen) and rabbit anti GFP antibody (Invitrogen). Alexa 546-conjugated anti-rabbit 
IgG was used as the secondary antibody.  
Results 
I successfully generated a T. gondii expression plasmid containing the 
CYGNET 2.1 insert. Restriction digestions confirmed the presence of the insert. The 
efficiency of transfection of T. gondii with the plasmid was very low in comparison to a 
control plasmid in spite of optimizing the protocol. I eventually resorted to cloning out 
positive CYGNET 2.1 expressing parasites using the cell sorter. Positive parasites were 
sorted into 96 well plates. Either one or five parasites were sorted into each well. Plaques 
were visible only in wells containing five parasites. Once the parasites from the wells 
were grown out, immunofluorescence assay using antibodies against PKG and YFP were 
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performed after every passage. The percentage of positive parasites (Figure II-15) 
decreased with each passage. This suggests that expression of CYGNET 2.1 interferes 
with parasite viability in some way.  
QuickTime™ and a
TIFF (Uncompressed) decompressor
are needed to see this picture.
 
Figure II- 15 Immunofluorescence of CYGNET 2.1 expressing parasites 
 
 
 
Immunofluorescence was performed with anti-PKG antibody and Alexa 546-conjugated anti-
rabbit IgG. The phase, fluorescence and merged images are shown. 
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Discussion 
As mentioned earlier, little is known about cyclic nucleotide signaling in 
T. gondii. Cyclic nucleotides haves been shown to play a important role during tachyzoite 
to bradyzoite differentiation (Kirkman, Weiss et al. 2001) and growth of T. gondii in vitro 
(Choi, Nam et al. 1990). I attempted to generate CYGNET 2.1-expressing parasite lines 
to measure the levels of cGMP and study its role during invasion. Unfortunately, I was 
unable to generate a stable parasite line expressing CYGNET 2.1. This suggests that the 
parasites are unable to tolerate CYGNET 2.1 expression. While I was unsuccessful in 
generating a stable T. gondii strain expressing CYGNET 2.1, parasites transiently 
expressing the construct could be a useful tool as well. However, it might still be a 
challenge to study the cGMP levels in transiently expressing parasites. The CYGNET 2.1 
system has been used to study cGMP levels in vascular smooth muscle cells successfully. 
These cells are big and easy to see under the microscope. T. gondii is significantly 
smaller and it may be hard to visualize changes in cGMP levels. Considerable 
optimization will be required before we can use this tool for studies in T. gondii.  
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 CHAPTER III 
 
Effect of invasion inhibitors on egress 
 
Introduction 
 
As described in chapter 1, T. gondii tachyzoites can invade any nucleated 
cell from warm-blooded animals. They reside within the PVM and replicate. When there 
are approximately 128 parasites within a vacuole, the parasites lyse the host cell and 
egress. The process of egress is not as well characterized as invasion. However, studies 
on egress mutants using calcium ionophore have shown that an increase in intracellular 
calcium induces egress (Arrizabalaga and Boothroyd 2004; Arrizabalaga, Ruiz et al. 
2004). Although it was initially thought that egress was a passive process that occurred 
by rupturing of the host cell membrane, it has now been shown that a moving junction, 
similar to that formed during invasion, forms during egress (Black and Boothroyd 2000; 
Alexander, Mital et al. 2005). A change in the host cell cytoplasmic potassium 
concentration is also thought to play a role in triggering egress. Just before egress, the 
PVM and host cell membrane are thought to become permeable and this results in a 
decrease of intracellular potassium, followed by egress of parasites (Moudy, Manning et 
al. 2001). To learn more about the process of egress, I tested the inhibitors of invasion 
identified in our high throughput screen for their effect on egress.  
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Method 
The egress assay was performed as described (Arrizabalaga, Ruiz et al. 
2004). 40mM stocks of the compounds were prepared in DMSO and diluted to 
appropriate concentrations in modified HBSSc (1 mM magnesium chloride, 1 mM 
calcium chloride, 10 mM sodium bicarbonate, and 20 mM Hepes, pH 7.2). 
Approximately 500 YFP expressing parasites were inoculated on a cover slip (18mm) 
with a confluent monolayer of human foreskin fibroblast cells. 30hrs post infection, the 
cover slips were washed with 1% PBS and then incubated with the compound for 15min 
at 23˚C. 5 μm Ionomycin (from a 1mM DMSO stock) in HBSSc with or without 
compound were added to the coverslip on ice. The equivalent volume of DMSO was used 
as a control. The coverslips were shifted to 37˚C for 5min and then were washed gently 
with 1% PBS. Coverslips were fixed with cold 100% methanol for 10min on ice, gently 
washed thrice with 1% PBS and visualized on the inverted fluorescence microscope at 
20X using a YFP filter. The numbers of lysed and intact vacuoles were counted and the 
percentage of intact vacuoles calculated. 
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 Results 
 
I  performed the egress assays with 8 of the invasion inhibitors. 4 out of 
the 8 compounds tested were non-toxic to the host cells (data not published). 2 of the 
compounds,144146 and 156579 do not inhibit T. gondii motility. The graph below 
represents the results from three independent assays (Figure III-1). The compounds 
inhibit egress to a varying extent. 267405 has no detectable effect on egress, even though 
it is an inhibitor of invasion and motility. Of the compounds tested, 144146 appears to 
inhibit egress the most.    
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Figure III- 1 Egress assay with compounds 
Values are expressed relative to the extent of egress seen after DMSO treatment (100%)
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I did dose response assays with 115546 and 118793. There seems to be a 
direct correlation between the concentration and amount of inhibition for both 
compounds (Figure III-2). 
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 Discussion 
Using the above-described assay, I have tested the effect of T. gondii 
invasion inhibitors on egress. All the compounds I tested are inhibitors of T. gondii 
invasion. However, two of the compounds, 144146 and 156579 do not inhibit motility but 
inhibit egress. In fact, 144146 inhibits egress to the greatest extent of any of the 
compounds tested. 144146 inhibits ionophore-induced conoid extension. It also appears 
to inhibit ionophore-induced egress. This suggests that 144146 possibly inhibits calcium 
signaling. It is also possible that conoid is involved in the process of egress.  
The other interesting outcome of this assay was 267405 does not inhibit 
egress although it inhibits motility and invasion. The dogma in the field is that invasion 
and egress are similar processes and that both require motility (Arrizabalaga and 
Boothroyd 2004; Morgan, Evans et al. 2007). The result with 267405 contradicts this 
dogma and raises many interesting questions. It is possible that the process of egress is in 
fact slightly different from invasion. Maybe a different subset of proteins are used during 
invasion which are not essential for egress. One of these proteins may be the target of 
267405. The egress assay was performed by inducing egress using a calcium ionophore. 
It would be of interest to test the same compounds for their effect on non-induced egress. 
However, non-induced egress assays require that parasites are treated with the compound 
at least six to seven hours before natural egress is observed (Black, Arrizabalaga et al. 
2000). During the invasion assays the parasites were treated for 15 min with the 
compounds. In the egress assay, leaving in the compounds for six to seven hours may 
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cause different effect. One way to get around this would be to treat the parasites for 
15min in the egress assay. However, if the effect of the compound is reversible, then by 
washing away the compound after a 15min treatment, I might see no phenotype. It will be 
interesting to test all the 24 inhibitors of invasion in the non-induced egress assay and in 
the induced egress assay and see if the results are the same. It will also be interesting to 
test the six enhancers of invasion to see if the enhancers enhance or induce egress. 
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 SUMMARY 
 
 
Various biologically essential and important proteins have been identified 
and studied using small molecule approaches. A library of small molecules can be 
screened in an assay that results in a particular phenotype, followed by identification of 
the target of the compound. Two approaches can be taken using small molecules. The 
first is a non-presumptive approach. A library of structurally diverse small molecules 
with no known targets is screened. The second approach is to screen a library of 
compounds with known targets. The second approach generates hypotheses that can be 
tested. In our lab, a non-presumptive high throughput screen of approximately 12,000 
compounds was performed to identify inhibitors of T. gondii invasion (Carey, Westwood 
et al. 2004). Another screen with 480 compounds with known targets was also performed 
(unpublished data).  
In this thesis, I have described the work I did with invasion inhibitors 
identified in the above-mentioned non-presumptive high throughput screen. I tested the 
hypothesis that 118793 is an inhibitor of cGMP PDE and also tested the small molecules 
for their role in egress. It will be interesting to identify the target of compounds that 
inhibit invasion but not egress. It will also be interesting to identify targets of compounds 
that inhibit just egress and not motility. Induced egress is thought to involve active 
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motility of parasites (Black, Arrizabalaga et al. 2000). If we identify a small molecule 
that inhibits motility but not egress, then the above theory should be revisited. 
During my Masters work, I have generated a tool to 
study cyclic nucleotide signaling in T. gondii. CYGNET 2.1 is sensitive to cGMP 
concentrations and highly specific for cGMP (Honda, Sawyer et al. 2005). Although I 
was unable to generate a stable parasite line expressing CYGNET 2.1, it would still be 
worthwhile to try measuring the cGMP levels in parasites transiently expressing 
CYGNET 2.1. I have also generated some preliminary data on the effect of 118793 on 
cGMP PDE. From these data it is hard to conclude whether 118793 has an effect on 
parasite PDE. However, it is clear that 118793 does not inhibit purified bovine PDE. 
Thus, it is possible that 118793 does not target cGMP PDE in T. gondii. As mentioned 
earlier, 118793 in structurally similar to an inhibitor of mammalian cGMP PDE. The 
region that interacts with the cGMP PDE enzyme is known for this inhibitor. Our 
collaborators have generated many different derivatives of 118793, which are modified in 
the region the mammalian inhibitor is thought to interact with cGMP PDE. From the 
SAR studies, modifying 118793 in this region does not affect 118793 inhibitory activity. 
This suggests that 118793 has different SAR characteristics and could have a completely 
different target. As mentioned in chapter 2, 118793 is identical to an inhibitor of 
mammalian kinesin Eg5. It might be worth revisiting the question if kinesins are a target 
of 118793 in T. gondii. Disrupting a kinesin could affect many processes in the cell, 
hence applying genetic strategies to study kinesins could be problematic. Thus, different 
methods of identifying the target of 118793 are in progress in our lab. We are trying to 
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radiolabel 118793 to perform drug western assays (Tanaka, Ohshima et al. 1999; Evans, 
Haraldsen et al. 2007). We have also generated a methotrexate-conjugated 118793 
molecule for yeast three hybrid assays (Baker, Sengupta et al. 2003). 118793 could also 
be linked to an affinity matrix, which might prove to be a useful tool to identify its target.  
Analysis of the signaling events involved in invasion is still at an early 
stage. Studies suggest calcium plays an important role during invasion. Intracellular 
calcium stores, which include acidocalcisomes, mitochondria, and the endoplasmic 
reticulum in T. gondii, trigger microneme discharge (Moreno and Zhong 1996; 
Carruthers and Sibley 1999). As mentioned in chapter 1, microneme proteins are 
important for adhesion and invasion (Carruthers, Giddings et al. 1999). It has been shown 
that during motility, the levels of calcium fluctuate, however during invasion the level of 
calcium decreases (Lovett and Sibley 2003).  Whether or not 118793 inhibits cGMP 
PDE, it will still be worth pursuing the role of cGMP in invasion. Known inhibitors of 
PDE, guanylate cyclases and cGMP analogs were tested in our invasion assay. Various 
compounds had varying effects on invasion. These results and the study showing the 
importance of PKG during invasion (Wiersma, Galuska et al. 2004) suggest an important 
role for cGMP during invasion. 
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